Imolopera (Loperamide Hydrochloride)

Imolopera (loperamide) acts on the gastrointestinal tract by slowing intestinal transit, thereby reducing excessive bowel movements associated with several diarrheal disorders.

• Acute nonspecific diarrhea: decreases stool frequency, improves stool form, and helps restore normal hydration status.
• Chronic diarrhea: provides ongoing symptomatic control of persistent loose stools, supporting daily activities and nutritional intake.
• Irritable bowel syndrome with diarrhea: alleviates diarrhea‑predominant symptoms, reduces urgency, and contributes to improved quality of life.

• Loperamide is a peripherally acting μ‑opioid receptor agonist that binds to receptors in the myenteric plexus of the intestinal wall. Activation inhibits acetylcholine release, reducing smooth‑muscle contractility and prolonging intestinal transit time. The drug also diminishes intestinal secretions, resulting in firmer stools and fewer bowel movements without significant central nervous system effects.

Loperamide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Constipation: hard stools or difficulty passing stool.
• Abdominal cramps: mild to moderate discomfort.
• Nausea: feeling of queasiness.
• Dry mouth: reduced salivation.
• Dizziness: light‑headed sensation.
• Drowsiness: mild sedation.

Serious or Rare Side Effects

• Severe constipation or bowel obstruction: risk of ileus.
• Toxic megacolon: rare but life‑threatening colonic dilation.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Cardiac arrhythmia: QT prolongation in susceptible individuals.
• Urinary retention: difficulty urinating.
• Central nervous system depression: excessive sedation or respiratory depression (rare).

Before using Imolopera, consider the following safety measures to minimize risks and ensure appropriate use.

• Do not exceed recommended dose: follow prescriber or label instructions.
• Use caution in hepatic impairment: reduced metabolism may increase drug levels.
• Avoid in children under two years: risk of severe constipation.
• Do not use for infectious diarrhea caused by Clostridioides difficile or invasive bacteria: may worsen condition.
• Consult a healthcare professional if diarrhea persists longer than two days or is accompanied by fever or blood.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Loperamide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Concurrent use with other opioid antidiarrheals (e.g., diphenoxylate‑atropine): may cause additive opioid effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase loperamide plasma concentrations, raising risk of cardiac toxicity.
• Drugs that prolong QT interval (e.g., quinidine, methadone): may enhance risk of arrhythmia.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents (e.g., diphenhydramine): may intensify constipation.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): may increase sedation.
• Medications affecting gut motility (e.g., metoclopramide): may alter therapeutic effect.
• Immunosuppressants (e.g., tacrolimus): potential for altered metabolism.